Online inquiry

IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2036MR)

This product GTTS-WQ2036MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens; Humanized
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ2036MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7554MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GC33
GTTS-WQ11407MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI-575
GTTS-WQ1775MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ14493MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RYI-018
GTTS-WQ5489MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CDP 6038
GTTS-WQ5497MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP 6038
GTTS-WQ7108MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FE 999301
GTTS-WQ6390MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CSL654
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW